An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HT1A Receptor

doi: 10.1021/acs.jnatprod.4c00977.

Online ahead of print.

Mehdi Haghdoost¹, Yvonne DePorre², Max Figi², Scott Young², Caitlyn Krebs¹, Marcel O Bonn-Miller²

Affiliations

PMID: 39811943
DOI: 10.1021/acs.jnatprod.4c00977

Abstract

Cannabicyclol ((±)-CBL), a minor phytocannabinoid, is largely unexplored, with its biological activity previously undocumented. We studied its conversion from cannabichromene (CBC) using various acidic catalysts. Montmorillonite (K30) in chloroform at room temperature had the highest yield (60%) with minimal byproducts. Key reaction conditions, such as solvent, temperature, and time, significantly impacted the yield. The structure of (±)-CBL was confirmed via X-ray crystallography. Stability studies showed that (±)-CBL and its MCT oil dilution remain stable at 25-40 °C for three months. Radioligand binding assays revealed high affinity of CBL for the 5-HT_1A receptor but weak interaction with CB₁ and CB₂ receptors. At 10 μM and 1 μM, (±)-CBL inhibited [³H]-8-hydroxy-DPAT binding to 5-HT_1A by 75% and 20%, respectively. Functional assays showed that (±)-CBL acts as a weak agonist at high concentrations but a potent positive allosteric modulator of serotonin-induced activation at low concentrations. At 4 μM, (±)-CBL increased serotonin-induced β-arrestin recruitment from 20% to 80%. This unique modulatory profile highlights the potential of (±)-CBL in drug discovery targeting serotonin receptors.

PubMed Disclaimer

Similar articles

Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.

Salisbury L, Baraitser L.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5.PMID: 36137063 Free Books & Documents. Review.
Enabling Systemic Identification and Functionality Profiling for Cdc42 Homeostatic Modulators.

Malasala S, Azimian F, Chen YH, Twiss JL, Boykin C, Akhtar SN, Lu Q.bioRxiv [Preprint]. 2024 Jan 8:2024.01.05.574351. doi: 10.1101/2024.01.05.574351.Update in: Commun Chem. 2024 Nov 19;7(1):271. doi: 10.1038/s42004-024-01352-7PMID: 38260445 Free PMC article. Preprint.
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D.Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.Retraction in: Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416PMID: 32205204 Free PMC article. Clinical Trial.
Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.

Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O’Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, Everitt H, Watson JC, Hay AD, Gillett P, Robins G, Jones HE, Mallett S, Whiting PF.Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371.PMID: 36321689 Free PMC article.
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.PMID: 36161421 Free PMC article. Review.